Real-time
Euronext Paris
01:27:51 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.236
EUR
|
-0.32%
|
|
-6.51%
|
-9.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
128.9
|
137.9
|
247.8
|
164.8
|
137.8
|
124.7
|
-
|
-
|
Enterprise Value (EV)
1 |
114.3
|
129.9
|
214.9
|
151.4
|
139.4
|
141.1
|
163.1
|
205
|
P/E ratio
|
-6.74
x
|
-7.85
x
|
-12.1
x
|
-5.02
x
|
-6.23
x
|
-8.86
x
|
-5.9
x
|
-2.95
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.39
x
|
13.9
x
|
14.2
x
|
15.9
x
|
17.4
x
|
3.13
x
|
2.5
x
|
4.18
x
|
EV / Revenue
|
8.32
x
|
13.1
x
|
12.3
x
|
14.6
x
|
17.6
x
|
3.54
x
|
3.27
x
|
6.88
x
|
EV / EBITDA
|
-4.63
x
|
-5.85
x
|
-10.2
x
|
-5.37
x
|
-4.9
x
|
-12.1
x
|
-8.63
x
|
-4.67
x
|
EV / FCF
|
-4.73
x
|
-4.39
x
|
-6.59
x
|
-6.94
x
|
-1,408
x
|
-11.2
x
|
-8.15
x
|
-5.16
x
|
FCF Yield
|
-21.1%
|
-22.8%
|
-15.2%
|
-14.4%
|
-0.07%
|
-8.93%
|
-12.3%
|
-19.4%
|
Price to Book
|
1.96
x
|
2.74
x
|
3.69
x
|
4.38
x
|
-
|
-6.89
x
|
-3.1
x
|
-1.53
x
|
Nbr of stocks (in thousands)
|
83,190
|
83,677
|
97,576
|
99,370
|
1,00,566
|
1,00,549
|
-
|
-
|
Reference price
2 |
1.550
|
1.648
|
2.540
|
1.658
|
1.370
|
1.240
|
1.240
|
1.240
|
Announcement Date
|
11/03/20
|
10/03/21
|
16/03/22
|
16/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.73
|
9.915
|
17.41
|
10.34
|
7.9
|
39.8
|
49.8
|
29.8
|
EBITDA
1 |
-24.68
|
-22.21
|
-21
|
-28.22
|
-28.48
|
-11.7
|
-18.9
|
-43.9
|
EBIT
1 |
-25.45
|
-23.99
|
-23.52
|
-29.9
|
-30.05
|
-15.7
|
-23.9
|
-46.9
|
Operating Margin
|
-185.35%
|
-241.99%
|
-135.1%
|
-289.1%
|
-380.34%
|
-39.45%
|
-47.99%
|
-157.38%
|
Earnings before Tax (EBT)
|
-
|
-17.23
|
-19.54
|
-32.8
|
-
|
-
|
-
|
-
|
Net income
1 |
-18.8
|
-17.23
|
-19.54
|
-32.8
|
-22.33
|
-13.8
|
-21.1
|
-41.4
|
Net margin
|
-136.93%
|
-173.79%
|
-112.19%
|
-317.13%
|
-282.63%
|
-34.67%
|
-42.37%
|
-138.93%
|
EPS
2 |
-0.2300
|
-0.2100
|
-0.2100
|
-0.3300
|
-0.2200
|
-0.1400
|
-0.2100
|
-0.4200
|
Free Cash Flow
1 |
-24.14
|
-29.59
|
-32.61
|
-21.84
|
-0.099
|
-12.6
|
-20
|
-39.7
|
FCF margin
|
-175.81%
|
-298.48%
|
-187.3%
|
-211.12%
|
-1.25%
|
-31.66%
|
-40.16%
|
-133.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/20
|
10/03/21
|
16/03/22
|
16/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 S1
|
2022 S2
|
---|
Net sales
1 |
-
|
4.257
|
EBITDA
|
-
|
-
|
EBIT
1 |
-
|
-15.07
|
Operating Margin
|
-
|
-353.98%
|
Earnings before Tax (EBT)
1 |
-
|
-17.52
|
Net income
1 |
-15.28
|
-17.52
|
Net margin
|
-
|
-411.67%
|
EPS
2 |
-0.1500
|
-0.1800
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
07/09/22
|
16/03/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
1.63
|
16.4
|
38.4
|
80.3
|
Net Cash position
1 |
14.6
|
7.99
|
32.9
|
13.3
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.0572
x
|
-1.402
x
|
-2.032
x
|
-1.829
x
|
Free Cash Flow
1 |
-24.1
|
-29.6
|
-32.6
|
-21.8
|
-0.1
|
-12.6
|
-20
|
-39.7
|
ROE (net income / shareholders' equity)
|
-36.7%
|
-29.7%
|
-33.1%
|
-62.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.7900
|
0.6000
|
0.6900
|
0.3800
|
-
|
-0.1800
|
-0.4000
|
-0.8100
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.73
|
0.85
|
0.69
|
1.54
|
-
|
4.8
|
6
|
3.6
|
Capex / Sales
|
12.6%
|
8.59%
|
3.94%
|
14.84%
|
-
|
12.06%
|
12.05%
|
12.08%
|
Announcement Date
|
11/03/20
|
10/03/21
|
16/03/22
|
16/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
1.24
EUR Average target price
3.5
EUR Spread / Average Target +182.26% Consensus |
1st Jan change
|
Capi.
|
---|
| -9.78% | 133M | | -1.17% | 104B | | +2.87% | 97.47B | | +3.76% | 22.25B | | -14.77% | 21.68B | | -9.03% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|